It is now more than 50 years since, in 1927, Sydney Campbell Dyke banded together the growing number of pathologists to form the British Pathologists' Association, which later became known as The Association of Clinical Pathologists. Dyke had a wide-ranging interest in medicine, unlike some of his successors, who have relinquished their clinical affiliations and have retired to the confines of their laboratories.
Under the influence of men such as Dyke, clinical pathology expanded into a discipline in which one had to be an expert in a wide range of pathological subjects and to have knowledge not only of their laboratory aspects but also of their clinical applications. With the advancement of medical science, however, it is no longer possible to be an expert in all aspects of the discipline, and many have neglected the clinical aspects.
Challenges are appearing on all sides. Within our laboratories some of the technical staffs believe that they should be in charge and that the medical pathologist should interest himself only in what are termed 'clinical matters'. This point of view has been propounded in the search for an elevation in status and the additional salary benefits that normally accompany it. The possible effects on evacuation of the mole and treatment is less than six months, and where there is no evidence of metastatic spread, constitute the low-risk category. A single, high-dose regime has also been tried, consisting of vincristine, 2 mg intravenously, followed 30 minutes later by the intravenous infusion of 2-5 g methotrexate in 500 ml normal saline administered over 6 hours. Folinic acid rescue is started 2 hours after the completion of the infusion, 6 mg being given intramuscularly 6-hourly for 12 doses.
The third dosage schedule is reserved for the resistant cases and involves the use of combinations of methotrexate, vincristine, actinomycin D, cyclophosphamide, vinblastine, and adriamycin (the 'triple regime').
RESULTS OF TREATMENT
Thirty-one patients were treated on the standard methotrexate-folinic acid regime and 27 went into remission. The remaining four required more aggressive therapy; using the 'triple regime' three were successfully controlled.
Twenty-seven patients were treated on the singledose methotrexate-folinic acid regime with 22 successful remissions. The remaining five were subsequently treated with the standard regime, four going into remission. Although the practical advantages of a single-dose regime are obvious, it was considered that the failure rate was unacceptably high, and this form of treatment has now been abandoned. The one failure on both regimes was then treated using the 'triple regime', with hysterectomy and radiotherapy to an unresectable pulmonary focus: she remains in remission.
One patient only has died, to give an overall remission rate of 98 3 0. Clomiphene citrate Clomiphene acts by competing with oestrogens for receptor sites in the hypothalamus, leading to an increase in the output of gonadotrophins. This in turn stimulates the maturation and endocrine activity of the ovarian follicle and subsequent development and activity of the corpus luteum.
It is administered at a dose level of 50 mg per day for five days, starting where appropriate on the fifth day of the cycle. The dose may be increased in subsequent cycles in the absence of a response. All patients collect 24-hour samples of urine for the six days after completion of the course of treatment to assess oestrogen output, and on days 20 and 22 for the estimation of pregnanediol as an assessment of luteal function. In subsequent courses collections of urine are made only on days 20 and 22 provided that the surge of oestrogen production was previously noted. Using clomiphene citrate and its related drugs, we have been successful in obtaining 165 pregnancies. The breakdown of these pregnancies is shown in Table 1 and is very different from the figures obtained with pituitary gonadotrophin. The multiple pregnancy rate is 2-4 % and the abortion rate 10-9 %.
Clomiphene citrate has been found to be of greatest Abortions 18 Twins 1 tTriplets 1 Abortions 10 9 % of the total number of pregnancies ended in abortion Multiple pregnancy 2-4 % of the total number of pregnancies were multiple 1-4 % of the total number of livebirths were multiple 11 1 % of the total number of abortions were multiple Table 2 it will be observed that there is a high incidence of pregnancy in those patients with the higher levels of prolactin excretion when first estimated. The converse is also clearly demonstrated.
Donor insemination
Infertile patients are referred to this laboratory because of azoospermia or severe oligospermia, and after hormonal investigation treatment is often begun with either mesterolone or clomiphene citrate. There remains a group of men in whom treatment does not elicit a response, and these are considered for donor insemination. To this group must be added those in whom there is an unacceptable risk of congenital abnormality or inherited disease, and those with a severe history of Rhesus incompatibility.
About 240 new couples are seen each year. They are initially referred for discussion and subsequent endocrine investigation. In suitable cases, donor insemination is offered, and the timing of insemination is based on the hormonal patterns found. Over 100 pregnancies have now been induced, between 50 and 60 % of the referred women obtaining their desired pregnancy.
Clinical pathology and those who practise this specialty are at a crossroads. The bridge between the laboratory and the patient must remain. The alternative is a further isolation of the laboratory and eventual domination by non-medical personnel; this would be to the detriment of the patient. We must become, if this has not already occurred, latter-day Sydney Dykes, expand from our 'laboratory shrines', and, in the best traditions of the founder of The Association of Clinical Pathologists, extend our influence as versatile experts both in the laboratory and in various specialised clinical fields. 
